Where can I find news about ACAD?

The latest headlines, third-party analysis, and SEC filings for ACADIA Pharmaceuticals Inc. (ACAD) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are ACAD's SEC filings?

ACADIA Pharmaceuticals Inc. (ACAD)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are ACAD's earnings call transcripts?

Full earnings call transcripts for ACADIA Pharmaceuticals Inc. (ACAD) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

ACAD

ACADIA Pharmaceuticals Inc.

NASDAQ·Biotechnology · Healthcare

$28.02$0.16+0.57%

Pre-market·$27.80−0.79%

Market cap$4.80B·Market closed·Sep 4 8:00 PM UTC

News & Analysis

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
zacks.comSep 3, 2026 · 12:31 PM
Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD
Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA
defenseworld.netSep 1, 2026 · 4:32 AM
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
zacks.comAug 24, 2026 · 11:06 AM
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
gurufocus.comAug 24, 2026 · 4:00 AM
BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD
BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals
defenseworld.netAug 24, 2026 · 3:56 AM
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.
businesswire.comAug 24, 2026 · 3:01 AM
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
marketbeat.comAug 12, 2026 · 3:04 PM
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
zacks.comAug 7, 2026 · 10:41 AM

SEC Filings

SC 13G
Aug 7, 2026View on SEC
10-Q
Aug 4, 2026View on SEC
8-K
Aug 4, 2026View on SEC
S-8
Jun 10, 2026View on SEC
8-K
May 29, 2026View on SEC
10-Q
May 6, 2026View on SEC

Frequently Asked Questions About ACAD

Where can I find news about ACAD?: The latest headlines, third-party analysis, and SEC filings for ACADIA Pharmaceuticals Inc. (ACAD) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are ACAD's SEC filings?: ACADIA Pharmaceuticals Inc. (ACAD)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are ACAD's earnings call transcripts?: Full earnings call transcripts for ACADIA Pharmaceuticals Inc. (ACAD) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

ACADIA Pharmaceuticals Inc.

Frequently Asked Questions About ACAD

ACADIA Pharmaceuticals Inc.

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Frequently Asked Questions About ACAD

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?